Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices

NEW TAIPEI CITY, Dec. 19, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE: 6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan Stock Exchange (TWSE). Effective December 23, 2024, Caliway's inclusion highlights its growing influence in the pharmaceutical and healthcare industries, reinforcing its position as a key player within the global biotech community.

The FTSE TWSE Taiwan Mid-Cap 100 Index, established in 2004, tracks the top 100 mid-cap companies in Taiwan by market capitalization, excluding the top 50 constituents of the FTSE TWSE Taiwan 50 Index. This index predominantly captures growth-focused sectors, reflecting the dynamic potential of companies like Caliway that are poised for expansion.

The FTSE TWSE Taiwan Eight Industries Index, launched in 2007, represents the performance of Taiwan's eight major industry sectors, highlighting companies with leading positions in their respective fields. Inclusion in this index underscores Caliway's strong presence and leadership within Taiwan's thriving biopharmaceutical sector.

Caliway's inclusion in these indices signifies its strong market performance, growth prospects, and increasing visibility within both local and international investment communities. As a company dedicated to innovation in biopharmaceuticals, this achievement aligns with Caliway's vision of delivering groundbreaking therapeutic solutions while creating value for its stakeholders.

Caliway will continue to leverage its innovative pipeline and strong market positioning to contribute to the biopharmaceutical industry's evolution in Taiwan and globally. 

About FTSE TWSE Taiwan Index Series

The FTSE TWSE Taiwan Index Series is a joint effort between the Taiwan Stock Exchange Corporation (TWSE) and FTSE Russell to provide market participants with a range of tools to gain visibility to the Taiwanese market. The index series comprises a range of real-time indices, which are designed as tools for use in the trading of derivatives, index-tracking funds, exchange-traded funds and as performance benchmarks.

About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals Co., Ltd. (TWSE: 6919) is a clinical-stage pioneering biopharmaceutical company focusing on developing cutting-edge therapeutics. Caliway aims to redefine patient outcomes through innovation.

Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.

For more information, please visit:
www.caliway.com.tw
https://taiwanindex.com.tw/news/337

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices

ROAD TOWN, British Virgin Islands, July 11, 2026 /PRNewswire/ -- AFX, a high-performance sovereign L1 purpose-built for decentralized derivatives, today announced a landmark operational milestone: surpassing $1.1 billion in cumulative trading volume during its initial period of operation. This rapid ascent is supported by over 8.6 million total trades, positioning AFX as one of the fastest-growing decentralized derivatives platforms in the 2026 Web3 landscape.

The most distinctive feature of AFX's growth is its superior capital efficiency. While many decentralized protocols rely on massive Total Value Locked (TVL) to attract volume, AFX has achieved its $1.1 billion milestone with a lean TVL of approximately $23.4 million.This exceptionally high volume-to-TVL ratio underscores the platform's advanced liquidity architecture and its appeal to professional high-frequency traders who demand deep order books and sub-100ms execution without the friction of legacy DeFi systems.

"Reaching $1.1 billion in volume so quickly validates our vision of a high-velocity, community-centric financial infrastructure," said Ken C, Head of Growth at AFX. "AFX is not just another DEX; it is a demonstration of how institutional-grade liquidity can thrive in a fully decentralized, sovereign environment. By allocating 65% of the token supply to the community, we are ensuring that the value generated by this high-performance engine is returned to the builders and traders who power it."

Currently, AFX is in the midst of its Season 1 Rewards program, featuring a 475,000 weekly points pool to incentivize liquidity providers and guild participants. The platform's LP Vaults (ALP) continue to deliver robust performance, offering an approximately 11% APY derived directly from actual protocol fees. As AFX continues to scale its 39 listed markets, including crypto leaders and synthetic TradFi assets, the protocol remains committed to bridging the gap between centralized performance and decentralized sovereignty.

About AFX

AFX is a high-performance sovereign L1 purpose-built for decentralized derivatives. By synthesizing the rapid execution of a centralized exchange with the immutable sovereignty of blockchain, AFX delivers a professional-grade Perp DEX environment characterized by sub-100ms finality, institutional liquidity, and unmatched capital efficiency.

Product availability varies by jurisdiction.

 

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

AFX Surpasses $1.1 Billion in Total Trading Volume, Highlighting Capital Efficiency in On-Chain Derivatives